arrow
J

Joseph Muenzer

takeda pharmaceuticals international, inc.
H指数:48
被引数:9,600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the hunter outcome survey

黏多糖贮积症II型患者18年临床特征与真实世界结局:Hunter结局调查最终报告

2025-11-020
PRE
Interim analysis of a phase 1/2 study of weekly intravenous DNL310 (brain-penetrant enzyme replacement therapy) in mucopolysaccharidosis type II
2024-02-011
PRE
Somatic outcomes in a phase 1/2 study of weekly intravenous DNL310 (brain-penetrant enzyme replacement therapy) in mucopolysaccharidosis type II
2024-02-010
PRE